Background

Children have the highest rates of influenza infection and school-aged children are the major vectors for influenza transmission that spread the virus to adults and the elderly in the community, causing substantial socioeconomic impact.1 For these reasons, the U.S. Centers for Disease Control and Prevention (CDC) recommends annual seasonal influenza vaccination for all eligible persons in the U.S., including eligible children aged 6 months through 18 years of age.2 Despite this, vaccination rates for school-aged children 5 to 17 years of age remain low, ranging from 24.6% (healthy) to 34.7% (high-risk) in the 2008-09 influenza season.2

To increase seasonal influenza vaccination rates, stakeholders have explored new immunization strategies including the routine vaccination of school-aged children.3 Previous research has demonstrated that increased vaccination of children could modulate the spread of influenza in the community. Mass vaccination programs in schools have demonstrated both direct benefits to immunized children and indirect benefits to the community including reduced school absenteeism due to influenza.4,5,6

An example of the benefits of influenza vaccination in school settings is:

• The Knox County (Tennessee) Health Department demonstrated program feasibility in a large public school system by vaccinating 24,198 students (56% among elementary schools, 45% among middle schools, and 30% among high schools) and 3,626 school staff from October to December 2005.7 Similarly, three Minnesota county health departments vaccinated 41% of all school children (K-12) in 2006. The study reported that school-based immunization programs offer the potential to achieve higher vaccination coverage of school children at modest cost.8

Past research supports the feasibility and benefits of conducting school-based influenza vaccination programs in terms of increasing vaccination in children, reducing school absenteeism and protecting the community from influenza. To help ensure pandemic preparedness and to establish an infrastructure for seasonal influenza vaccination of children, states should adopt school-based influenza vaccination programs to protect the public health.

1 Neuzil KM, et.al. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002;156:986-991.
2 At http://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0729a1.htm?s_cid=rr59e0729a1_w. August 10, 2010.
3 Longini IM and Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005;161:303-306.
4 Principi N, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J. 2003:22:S207-10.
5 Wiggs-Stayer KS, et al. The impact of mass immunization on school attendance. J School Nursing. 2006;22:219-222.
6 Davis MM, King JC, Moag L, et. al. Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008;122:e260-e265.
7 Carpenter LR, Lott J, Lawson BM, et. al. Mass distribution of free, intranasally administered influenza vaccine in a public school system. Pediatrics 2007;120:e172-e178
8 Hull HF, Frauendienst RS, Gundersen ML, et. al. School-based influenza immunization. Vaccine 2008;26:4312-4313.

Download POSITION ON SCHOOL-BASED INFLUENZA VACCINATION PROGRAMS (PDF, 50.7KB)

“With the growing importance of influenza prevention, it is essential to better understand the current data on influenza vaccines as well as how best to provide them to children and adults in the United States,” said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. “The data being presented at the conference build on our extensive foundation of research and help advance innovative solutions for preventing illnesses that negatively impact the health of the U.S. population.”

 MedImmune abstracts to be presented at NIC on influenza include:

• “Parent’s Decision-Making for Immunizing Children Against Seasonal Influenza.” Flood, E.M., et al. Workshop in the Regency Ballroom VI: April 21, 2010 Time: 11:20AM.

• “Pediatric Office Characteristics and Activities Associated with Increased Influenza Vaccine Delivery.” Bhatt, P., et al. Workshop in the Centennial Ballroom I: April 22, 2010 Time: 9:20AM.

• “Relative Efficacy of Live Attenuated and Inactivated Influenza Vaccine in Children as a Function of Time Post Vaccination.” Belshe, R.B., et al. Poster Session in the Grand Hall: April 20-21, 2010 Time: 10 AM – 4 PM.

• “Preferences for Influenza Vaccines for Children: Do Children and Parents Agree?” Rousculp, M.D., et al. Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

• “High Inter-Office Variability in Pediatric Influenza Vaccination.”  Block, S.L., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

•  “Case Reports on Maternal and Fetal Outcomes After Exposure to LAIV During Pregnancy.” Toback, S.L., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

• “Elementary School-Based Influenza Vaccination Programs: Findings to Inform Pandemic Vaccination Campaigns.” Rousculp, M.D., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

•  “What do Children Know About Influenza and Influenza Vaccines?”  Ryan, K.J., et al. Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

• “Real-Time Assessment of 2009-2010 Influenza Vaccine Utilization Among Practicing Pediatricians.” Carr, W., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

•  “Live Attenuated Influenza Vaccine and Reduction in Influenza-Associated Acute Otitis Media in Children 24-83 Months.” Block, S.L., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM – 4 PM.

 Additional information about the 44^th National Immunization Conference can be found at http://www.cdc.gov/vaccines/events/nic/default.htm

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com

“MedImmune is dedicated to conducting ground-breaking research on the prevention of respiratory syncytial virus (RSV) and influenza in children,” said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. “We believe the data being presented at the conference may help advance innovative healthcare solutions for these important causes of respiratory infections in children.”

MedImmune abstracts to be presented at IDSA on RSV include:

• Prophylaxis Utilizing Nebulized Motavizumab, a Monoclonal Antibody Against Fusion Protein of Respiratory Syncytial Virus (RSV) Zhang J, et al. Poster Session: October 30, 2009; 12:30 – 2:00 PM; Poster Hall A / Poster # 608

BACKGROUND: Respiratory syncytial virus (RSV) infection is the primary cause of pneumonia and bronchiolitis in young children, and also causes disease in older adults. This study evaluated the prophylactic use of nebulized motavizumab, an investigational anti-RSV humanized monoclonal antibody against RSV fusion protein, in cotton rats. The findings suggest that prophylaxis with nebulized motavizumab may inhibit RSV infection and spread in the lungs and may provide an alternative to the current intramuscular antibody delivery.

MedImmune abstracts to be presented at IDSA on influenza include:

• A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine Use in Unapproved Children Less Than 59 Months of Age Tennis P, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1179

BACKGROUND: In September 2007, the approval of live attenuated influenza vaccine (LAIV) was expanded for use in children between 24 and 59 months in age. The vaccine was not approved for use in children younger than 24 months, or for use in children with asthma or recurrent wheezing, or those with altered immunocompetence. This study evaluates the usage and safety of the vaccine in those patient populations younger than 59 months of age that were not in the approved indication. The study found that healthcare providers appear to be complying with the indications for the use of LAIV in children <5 years, and no adverse safety outcomes were detected in the small number of children in unapproved groups who received the vaccine.

• Whole Genome Transcriptional Analysis of the Early Immune Responses Induced by Live Attenuated and Inactivated Influenza Vaccines in Young Children Zhu W, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1181

BACKGROUND: This study examined the early genomic immune response to live attenuated and inactivated vaccines in previously unvaccinated children 12 to 35 months of age. Among LAIV recipients, an increase in interferon (a natural anti-viral immune protein) production was seen, which may partly explain previous clinical study observations of LAIV-induced protection against illness in the first 2 weeks after administration.

• Influenza-Associated Antibiotic Use in Children Receiving Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine Belshe R, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1180

BACKGROUND: Influenza illness in children commonly results in the unnecessary use of prescription antibiotics. This analysis evaluated the efficacy of live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) in preventing antibiotic use in children ranging from six months to 17 years in age. Overall, there was less influenza-associated antibiotic use in LAIV recipients due to a lower rate of culture-confirmed influenza with LAIV.

###

Additional information about the 2009 IDSA conference can be found at http://www.idsociety.org/IDSA2009.htm.

About FluMist®

FluMist® (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life- threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.medimmune.com/pdf/products/flumist_pi.pdf for additional information.

About MedImmune, Inc.

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

NEW YORK, Aug. 20 /PRNewswire/ — MedImmune, Women’s Professional Soccer (WPS) and the American Youth Soccer Organization (AYSO) today officially launched “Don’t Play with the Flu,”(TM) a national health awareness campaign that aims to highlight the importance of getting a seasonal influenza vaccination every year. “Don’t Play with the Flu” kicks off today in New York City with a one-of-a-kind soccer clinic led by soccer legends and moms Mia Hamm and Brandi Chastain.

The U.S. Centers for Disease Control and Prevention (CDC) advises that the single best way families can help prevent the seasonal flu is by getting a flu vaccine – every year – for those individuals who are eligible to receive it. The CDC recommends that children 6 months through 18 years of age be vaccinated annually against seasonal flu and that eligible individuals be immunized as soon as the seasonal vaccine becomes available, which can be as early as August and September.

“We know a vaccine is the best way to help protect ourselves from the flu, so my family and I get a seasonal flu vaccine as soon as we can every year,” said Mia Hamm, international soccer legend and proud mother of 2-year-old twins. “That way we can concentrate on all the other things we regularly do to stay healthy on and off the field and in our busy lives.”

The campaign reminds families of one key soccer term, G.O.A.L., when thinking about seasonal influenza prevention:

• Get a seasonal flu vaccine every year for eligible family members.
• Options are available. Talk to your healthcare provider about what type of flu vaccine – the shot or the nasal spray – is right for you and your family members.
• Avoid germs and illness. Wash hands often, cover sneezes and coughs with a tissue or arm sleeve, avoid those who are sick, and keep yourself and family members home when sick.
• Lead a healthy lifestyle with plenty of sleep, proper nutrition, frequent exercise and plenty of liquids.

“Along with all the things that parents know are important for helping keep their kids healthy – like washing hands and getting enough sleep – influenza vaccination should be at the top of the list. It’s a smart defense to help protect our kids – and our families – from seasonal flu,” said Anat R. Feingold, M.D., a pediatric infectious disease expert. “And because kids can spread the flu, including at school, it’s important that parents ask about an annual flu vaccine as soon as it is available. Back-to-school and sports physicals can be the perfect opportunity.”

According to the CDC, each year, as many as 60 million Americans get the flu, and the resulting complications cause more than 200,000 hospitalizations. Children between 2 and 17 years of age are twice as likely to get the flu as adults and commonly need medical care. Flu can also impact school, with one analysis showing students missed approximately 38 million school days due to seasonal flu in one year.

The campaign offers families information, resources, and updates through DontPlaywiththeFlu.com. Parents and kids can find interactive content, including a quiz about seasonal flu, educational information, and insights into the lives of soccer stars, moms and role models Hamm and Chastain. The campaign also aims to educate families about the importance of seasonal flu vaccination for eligible individuals through informational brochures at WPS stadiums, media events and soccer clinics in WPS franchise cities, and directly to AYSO members and families around the country.

“‘Don’t Play with the Flu’ reflects MedImmune’s commitment to supporting healthy families,” said Tony Zook, president of MedImmune. “We’re very pleased to partner with Women’s Professional Soccer, the American Youth Soccer Organization, and of course Mia Hamm and Brandi Chastain, to bring this important preventive health message to families across the country this flu season.”

As a part of the campaign, MedImmune has become a sponsor of WPS, the world’s premier women’s professional soccer league, and AYSO, a nationwide non-profit youth soccer organization that develops and delivers quality youth soccer programs to approximately 600,000 players. MedImmune is the presenting sponsor of the 2009 WPS Championship in Los Angeles this Saturday, Aug. 22, and will also present the “Defender of the Year” award at the WPS All-Star Game in St. Louis on Sunday, Aug. 30. MedImmune manufactures FluMist (Influenza Vaccine Live, Intranasal), the nasal spray flu vaccine against seasonal influenza for eligible individuals 2 – 49 years of age. See important safety and eligibility information below.

For more information about today’s event, including time and location, please contact Paddi Hurley, Fleishman-Hillard, 917-743-2290 or paddi.hurley@fleishman.com.

Important Safety and Eligibility information for FluMist

Who may be eligible for FluMist (Influenza Vaccine Live, Intranasal)?

FluMist is a vaccine approved for the prevention of certain types of influenza disease in children, adolescents and adults 2-49 years of age. FluMist may not protect everyone who gets it. FluMist is for intranasal administration only.

Who may not be able to get FluMist?

FluMist is not right for everyone. FluMist must not be given to: people with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine; people with life-threatening reactions to previous influenza vaccinations; and children and adolescents receiving aspirin or aspirin-containing therapy. Children less than 24 months of age are not eligible for FluMist.

The following people may not be able to get FluMist or may be able to get it only in certain situations: people with asthma or active wheezing, or children less than 5 years of age with recurrent wheezing; people with a history of Guillain-Barre syndrome; people with a weakened immune system; people with long-term medical conditions including heart disease, kidney disease, and metabolic diseases, such as diabetes; and pregnant women.

If a child falls into one of these groups, a healthcare provider can decide if FluMist is right for that child.

What are the most common side effects of FluMist?

Most common side effects included runny nose or nasal congestion, sore throat, and fever. For a full list of side effects, please see section 6.1 in the following product information.

Please see the complete product information. For more information, please visit www.FluMist.com.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

About Women’s Professional Soccer

Women’s Professional Soccer (WPS) is the premier women’s soccer league in the world and the global standard by which women’s professional sports are measured. The Inaugural Season kicked off on March 29 and runs through August 30, 2009, with WPS teams based in the Bay Area, Boston, Chicago, Los Angeles, New Jersey/New York, St. Louis, and Washington, D.C. The league’s eighth and ninth franchises in Philadelphia and Atlanta will begin play in 2010. For more information, visit www.womensprosoccer.com.

About American Youth Soccer Organization

The American Youth Soccer Organization (AYSO) is the largest single-entity youth soccer association in the U.S. with nearly 600,000 players and 225,000 volunteers. AYSO develops and delivers quality youth soccer development programs in a fun, safe environment based on the Six Philosophies of Everyone Plays , Balanced Teams, Open Registration, Positive Coaching, Good Sportsmanship and Player Development. For questions about AYSO, please contact Sahar Milani at 310-727-5421 or SaharMilani@ayso.org.

SOURCE MedImmune
08/20/2009
/CONTACT: Karen Lancaster, MedImmune, +1-301-398-5864,
lancasterk@medimmune.com; Paddi Hurley, Fleishman-Hillard, +1-917-743-2290,
paddi.hurley@fleishman.com/
/Web Site: http://www.medimmune.com /
(AZN)

CO: MedImmune
ST: New York
IN: HEA MTC
SU: CHI

PR
– AQ64061 –
3361 08/20/2009 08:00 EDT http://www.prnewswire.com

MedImmune Announces Influenza Vaccination Awareness Campaign with Women’s Professional Soccer

GAITHERSBURG, Md., July 28 /PRNewswire/ — MedImmune announced today that it has begun shipping its seasonal influenza vaccine FluMist (Influenza Vaccine Live, Intranasal) to vaccine distributors who service health care providers throughout the United States. MedImmune expects approximately 10 million doses of its trivalent (three-strain) nasal spray flu vaccine will be available for the 2009-2010 influenza season through a variety of private health care practices, public health departments, school-based vaccination programs, military bases, and other locations.

The U.S. Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics advise that flu vaccine be administered every year as soon as it becomes available. A MedImmune analysis suggests that starting influenza vaccination in August instead of October may help reach an additional 11.5 million children at already-scheduled healthcare provider visits.

The 2009-2010 influenza season is the first for full implementation of the recommendations by the CDC’s Advisory Committee on Immunization Practices (ACIP) that children six months through the age of 18 years be vaccinated annually against influenza, meaning 30 million additional children 5 through 18 years of age now fall within influenza vaccination recommendations.

“MedImmune is committed to delivering our seasonal nasal spray influenza vaccine in the summer months in order to increase opportunities for vaccination,” said Alex Zukiwski, MD, MedImmune’s Executive Vice President, Clinical Research & Chief Medical Officer. “If more eligible children can be vaccinated against seasonal influenza while attending back-to-school checkups, sports physicals, and clinics early in the school year, the country will be better prepared for the flu season ahead.”

FluMist is available in every state through the federally funded Vaccines for Children (VFC) program, which provides vaccines at no cost to eligible children. FluMist is also covered by approximately 95 percent of private health plans which offer immunization benefits.

FluMist Becomes Sponsor of Women’s Professional Soccer

To help communicate the importance of seasonal flu vaccination efforts, MedImmune has teamed up with Women’s Professional Soccer (WPS) for “Don’t Play with the Flu”(TM) (www.dontplaywiththeflu.com), a national health awareness campaign with the goal of increasing seasonal flu vaccination rates among eligible kids and families across the country. As part of the multi-faceted campaign, FluMist has become an official sponsor of WPS, the world’s premier women’s professional soccer league, working with real-life soccer moms and the league to reach families during flu vaccination season, including back-to-school visits.

“Our ‘Don’t Play with the Flu’ efforts are directed toward parents to help them understand the importance of annual influenza vaccination and reminds them not to wait to put up a defense against the flu, particularly with seasonal vaccine becoming available during the summer,” said Peter Greenleaf, MedImmune’s Senior Vice President, Commercial Operations, Corporate Development & Strategy. “We’re proud to partner with the WPS in its inaugural season to bring this fun, educational and interactive campaign to the families across America.”

Important Safety and Eligibility information for FluMist

Who may be eligible for FluMist (Influenza Vaccine Live, Intranasal)?

FluMist is a vaccine approved for the prevention of certain types of influenza disease in children, adolescents and adults 2-49 years of age. FluMist may not protect everyone who gets it. FluMist is for intranasal administration only.

Who may not be able to get FluMist?

FluMist is not right for everyone. FluMist must not be given to: people with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine; people with life-threatening reactions to previous influenza vaccinations; and children and adolescents receiving aspirin or aspirin-containing therapy. Children less than 24 months of age are not eligible for FluMist.

The following people may not be able to get FluMist or may be able to get it only in certain situations: people with asthma or active wheezing, or children less than 5 years of age with recurrent wheezing; people with a history of Guillain-Barre syndrome; people with a weakened immune system; people with long-term medical conditions including heart disease, kidney disease, and metabolic diseases, such as diabetes; and pregnant women.

If your child falls into one of these groups, be sure to tell your healthcare provider. They will decide if FluMist is right for your child.

What are the most common side effects of FluMist?

Most common side effects included runny nose or nasal congestion, sore throat, and fever. For a full list of side effects, please see section 6.1 in the following product information.

Please see the complete product information.

For more information, please visit www.FluMist.com.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

SOURCE MedImmune

CONTACT: Karen Lancaster of MedImmune, +1-301-398-5864, lancasterk@medimmune.com/

GAITHERSBURG, Md., June 1 /PRNewswire/ — MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has awarded the company a contract to manufacture monovalent (single-strain) live attenuated influenza vaccine for Novel Influenza A (H1N1) to vaccinate priority populations identified by HHS in the National Strategy for Pandemic Influenza. An initial order of $90 million of vaccine has been placed, with the potential for additional orders. This project has been funded in whole or in part with the Federal funds from HHS/ASPR/BARDA, under Contract No. HHSO100200900002I.

MedImmune scientists have identified several promising vaccine candidates against the Novel Influenza A (H1N1) strain, and are currently evaluating their growth properties and antigenicity (i.e., their ability to stimulate antibodies) for mass production as part of the vaccine manufacturing process.

“MedImmune is pleased to be able to contribute our scientific expertise in influenza vaccine development and manufacturing to help combat this unpredictable public health threat,” said Ben Machielse, Drs., executive vice president of operations, MedImmune. “We are confident that our vaccine technology has several attributes that may be useful in protecting people with limited exposure to influenza against the Novel Influenza A (H1N1) strain.”

MedImmune’s live attenuated influenza vaccine (LAIV) technology may be particularly well-suited for vaccinating against emerging influenza strains. LAIV is different from the injectable influenza vaccine (“flu shot”) in that it is a gentle mist sprayed into the nose, where the influenza virus usually enters the body. It contains live vaccine virus strains that are weakened so as not to cause the flu, but prompt the body to mount an immune response after the first dose. Because it is live and stimulates a broad range of immune responses, LAIV may offer some cross-protection against circulating flu strains that are “drifted” – meaning they are very closely-related but not perfectly matched to the flu strains in the vaccine.

As a needle-free nasal spray, LAIV is well suited to facilitate mass vaccination, and has been widely used for school-based vaccinations and to help protect active-duty military personnel.

While MedImmune is committed to supporting global efforts to help protect individuals against the Novel Influenza A (H1N1) virus, its vaccine technology is currently only licensed in the United States. MedImmune is willing to make additional vaccine available to other governments if any capacity remains after fulfilling obligations to the U.S. government, assuming that necessary regulatory approval can be obtained.

Seasonal FluMist(R) on Track to Begin Shipping in August

MedImmune believes that the best way to help protect all eligible age groups against seasonal influenza is to vaccinate prior to and during the back-to-school period. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends influenza vaccination for all age groups as soon as seasonal vaccine is available each year. MedImmune plans to begin shipping the first of approximately 10 million doses of seasonal FluMist(R) (Influenza Virus Vaccine Live, Intranasal) to health care providers in August. This early availability of vaccine significantly widens the window of opportunity to vaccinate more eligible individuals and improve seasonal influenza vaccination rates, as patients seeing their providers for routine office visits can be vaccinated without waiting for the rush of fall vaccination clinics.

About Seasonal FluMist

FluMist(R) (Influenza Virus Vaccine Live, Intranasal) is a vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life- threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.flumist.com/prescribing-information.aspx for additional information.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

The opinions expressed herein do not represent opinions or statements made or expressed by the U.S. Department of Health and Human Services.

http://www.medimmune.com

SOURCE MedImmune

CONTACT: Karen Lancaster of MedImmune, +1-301-398-5864

GAITHERSBURG, MD, May 5, 2009 — Data presented suggest that FluMist® (Influenza Vaccine Live, Intranasal) has an acceptable safety profile among mild to moderately immunocompromised children with cancer.   The immune systems of children with cancer can be weakened due to cancer treatments, making them vulnerable to influenza or other infections.   The small multi-center, randomized, double-blind pilot study compared FluMist to placebo in 20 children, five to 17 years of age.   The results, along with data from 10 other MedImmune-sponsored, influenza-related studies, were presented at the 2009 Pediatric Academic Societies (PAS) annual meeting in Baltimore, MD.

In our pilot study, immunocompromised children with cancer who received FluMist had no related serious adverse events, explained Pat Flynn M.D., director, clinical research, infectious diseases, St. Jude Children’s Research Hospital. We believe these data are promising and add to the extensive body of evidence supporting the overall safety of FluMist in the population for whom it is approved.   A larger study will help us confirm the safe use of FluMist in immunocomprised patients.     The value of this type of research is even more apparent today as we all consider how best to protect all of our patients against the threat of emerging, new influenza viruses.

FluMist, a live attenuated influenza vaccine (LAIV), is the only nasal spray influenza vaccine approved in the United States to help prevent influenza in eligible individuals ages two to 49 years of age.   (Please see About FluMist for important safety and eligibility information later in this release).

Additional studies presented at PAS explored various aspects of FluMist, including its efficacy as a function of age from six months to 17 years of age*, results with only a single dose in previously unvaccinated children, and data regarding influenza-related ear infections.   Research also evaluated the effect of FluMist against opposite-lineage influenza B strains.  Other research focused on influenza vaccination practices of U.S. pediatricians during the 2007 — 2009 flu seasons and the impact of respiratory illness in children on parent work absenteeism and productivity.  

In a time when influenza prevention is receiving so much attention, MedImmune is pleased to share a number of new studies and analyses with the medical community as we work together to help protect our children and families from influenza, said Chris Ambrose, M.D., senior director, medical affairs, MedImmune.

Brief summaries of the ten (10) MedImmune-sponsored abstracts presented at PAS are provided below.

LAIV Use in Children

• In an abstract that reviewed data from multiple randomized, controlled studies among children six months to 17 years of age, LAIV efficacy against culture-confirmed influenza did not vary with age.   Compared to placebo, LAIV had high efficacy and this efficacy did not vary among children 15 to 84 months of age.     LAIV had higher efficacy in children six months to 17 years of age compared to the traditional injectable vaccine.* (Belshe R, #5529.501)    
• In an analysis of three randomized, double-blind studies, a single dose of LAIV in previously unvaccinated children two to six years of age provided significant protection against culture-confirmed influenza compared to placebo.   These findings are significant because most children who are recommended to receive two doses of influenza vaccine only receive one dose. The efficacy of one LAIV dose was approximately 90 percent of the efficacy of two doses.   Efficacy after revaccination in year two with a single dose was comparable whether the child received one or two doses in the previous year.   (Block, #5529.505)
• Across eight randomized, controlled studies, LAIV reduced influenza-associated acute otitis media (AOM) — commonly referred to as an ear infection — caused by influenza strains matched to the vaccine by 73 percent to 98 percent.   These data suggest that FluMist has the potential to reduce the burden of AOM in young children with influenza.   (Block S, #5529.504)
• An analysis of LAIV efficacy against opposite-lineage influenza B strains, against which efficacy of all influenza vaccines has been believed to be low or zero, was conducted with data from six randomized, double-blind studies.   In young children, LAIV may provide some efficacy against opposite-lineage influenza B strains, but this efficacy is lower than efficacy against influenza B strains of the same lineage as the vaccine.     Based on these findings, study authors suggest that quadrivalent vaccines containing influenza B strains of both lineages should be considered.   (Belshe R, #4357.473)
• In an analysis of a previously conducted study that compared LAIV and injectable influenza vaccine in children six to 59 months of age* and found 51 percent  fewer cases of influenza illness among LAIV recipients compared to injectable vaccine recipients, the amount of viral RNA recovered from subjects with breakthrough influenza illness was analyzed.   No statistically significant differences were seen, and analysis of infectious virus by cell culture will gather additional data.(Belshe R, 5529.502)

      *LAIV is not approved for use in children under two years of age.  

Influenza Vaccination Practices of U.S. Pediatricians

• Four additional MedImmune-sponsored studies evaluated influenza vaccination practices among U.S. pediatricians, based on a prospective, observational study of pediatric offices during the 2007-2009 flu seasons.   The principal conclusions of the studies included the following:
• Pediatric influenza vaccination rates in pediatric offices may have increased in 2008-09 compared to the previous year, and LAIV represented approximately one-third of the vaccinations given to children two to 18 years of age during the 2008-2009 season (Bhatt P, #5529.499)
• Pediatricians may be able to vaccinate more children by offering flu vaccine to their patients before October and after December (Bhatt P, #5529.500)
• Pediatricians are supportive of vaccinating parents in their offices (Toback S, # 5529.498)
• Generally, pediatric offices have little influenza vaccine left-over at the end of the influenza season (Block S, #5529.503)

Increased Employee Absenteeism Seen Among Adults from Homes Where Kids Had Influenza-like-Illness

• A final MedImmune-sponsored study presented at PAS prospectively followed 2,298 households during the 2007-2008 influenza season. (Rousculp M, #3866.255)  
• The research found that employed adults had increased work absenteeism in homes where children had influenza-like illnesses, as well as other acute respiratory illnesses.
• The study’s authors conclude that employers should evaluate opportunities to reduce influenza-like illnesses and other acute respiratory illnesses in both the employee and employee’s children in order to maximize employee productivity.

About FluMist

FluMist® (Influenza Virus Vaccine Live, Intranasal) is a vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life- threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.flumist.com/prescribing-information.aspx for additional information.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

NIJMEGEN, The Netherlands, January 6, 2009 — MedImmune, the global biologics unit of AstraZeneca, announced today that it has submitted a Marketing Authorisation Application (MAA) for its nasal spray live attenuated influenza vaccine (LAIV), which is now being reviewed by the European Medicines Agency (EMEA). The proposed indication in the MAA is for prevention of seasonal influenza.

The MAA submission for LAIV is based on data from 73 global clinical and U.S. post-marketing studies of more than 141,000 subjects ranging in age from 7 weeks to 97 years and conducted in 38 countries. Study objectives have included clinical safety and tolerability, clinical efficacy and effectiveness, and immunogenicity.

Influenza creates a heavy medical and economic burden on Europe and throughout the world, and we are hopeful that the future availability and product characteristics of this novel nasal spray influenza vaccine will contribute to an increase in vaccination rates and reduce the spread of influenza around the world, said Alex Zukiwski, M.D., executive vice president, clinical affairs and chief medical officer. MedImmune is pleased to submit this application for approval of our nasal spray influenza vaccine in Europe.

About LAIV
Each dose of LAIV is formulated to contain three live attenuated influenza virus strains, which are weakened as to not cause illness: Two Type A influenza strains (A/H1N1 and A/H3N2) and one Type B strain. The vaccine strains are selected annually by the World Health Organization (WHO) based on anticipated circulating influenza strains for the upcoming season. The vaccine is sprayed into the nose, rather than by injection as with other licensed influenza vaccines, where it induces protective immunity.

In the U.S., LAIV is marketed under the trade name FluMist® (Influenza Virus Vaccine Live, Intranasal). It was approved by the U.S. Food and Drug Administration in 2003. The vaccine included in the MAA has not been registered in the European Union (EU) and is not available outside of the United States.

About Influenza
Influenza is the most common vaccine-preventable disease in the developed world. According to WHO estimates, seasonal influenza results in three to five million cases of severe illness and up to half a million deaths globally each year, primarily among the elderly. Rates of infection are highest among children, with school-aged children significantly contributing to spread of disease to their families, communities and high-risk individuals.

Influenza also has socioeconomic consequences related to both direct and indirect health care costs, including hospitalizations, work absence and loss of work productivity when either a caregiver or child is sick with influenza.

In the EU, current guidelines recommend annual influenza vaccination for the elderly as well as those with underlying medical conditions such as chronic heart or lung disease. However, vaccination rates in the recommended groups throughout Europe are estimated to be only 35 percent (Ryan, Vaccine, August 2006).

To date, six EU countries (Finland, Austria, Estonia, Latvia, Slovakia and Slovenia) recommend routinely vaccinating young children against influenza with varying age limits. EU and Member State policymakers continue to evaluate data on the impact of influenza in children to best inform the potential expansion of recommendations.

About MedImmune
MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at http://www.medimmune.com.

Contacts
Media:
Chris Sampson, +44 (0)207 304 5130 (AstraZeneca)
Sarah Lindgreen, +44 (0)207 304 5033 (AstraZeneca)
Karen Lancaster, +1-301-398-5864 (MedImmune)

“MedImmune is committed to conducting innovative infectious disease research to determine how best to prevent serious illness that can negatively impact pediatric health, especially during this time of year,” said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. “We believe the data being presented at this meeting will help lead to important new healthcare solutions, and our company is proud to advance our already robust research base to identify the best ways to help protect children.”

MedImmune abstracts to be presented at ICAAC/IDSA on RSV include:

• Respiratory Syncytial Virus Therapy Utilizing Intranasally Delivered Motavizumab, a Monoclonal Antibody Against the Viral Fusion Protein (#V-4145) B. Richter, Tuesday, October 28, 2008, Hall C from 12:15 PM to 1:15 PM

BACKGROUND: A primary cause of pneumonia and bronchiolitis in young children is RSV infection. This preclinical study examined the therapeutic effect of topically administered motavizumab.

• Therapeutic Addition of Motavizumab, a Monoclonal Antibody Against Respiratory Syncytial Virus, Modulates Epithelial Cell Responses to RSV Infection (#V-4146) S. Krishnan, Tuesday, October 28, 2008, Hall C from 12:15 PM to 1:15 PM

BACKGROUND: RSV infection of epithelial cells leads to inflammatory host responses. This preclinical study tested whether motavizumab, a humanized monoclonal antibody against the RSV fusion (F) protein, could modulate epithelial cell immune responses to RSV. Lower and upper airway epithelial cells were infected with RSV and motavizumab or a control antibody was subsequently administered at various points post-infection to evaluate the therapeutic addition.

• Total Healthcare Costs of Preterm Infants with Medically Attended Respiratory Syncytial Virus Lower Respiratory Infection (#K-1429 ) D. Stewart, Sunday, October 26, 2008, Hall C from 12:15 PM to 1:15 PM

BACKGROUND: While RSV lower respiratory infection (LRI) is the most common cause of hospitalization among infants under one year of age, the total healthcare costs of medically attended RSV LRI for babies of this age group is unknown. This retrospective, propensity-matched cohort assessment sought to determine first-year healthcare costs by examining premature infants born over a five-year period who were insured by a national U.S. health plan, including a subgroup analysis of babies born between 33 and 36 weeks gestation.

• In Vitro Mechanism of Action Studies of the RSV-Neutralizing Monoclonal Antibodies Palivizumab and Motavizumab (#V-4146) K. Huang, Tuesday, October 28, 2008, Hall C from 12:15 PM to 1:15 PM

BACKGROUND: Synagis is the only licensed drug product available to help prevent lower respiratory tract RSV infection in premature infants, a leading cause of hospitalizations in this patient population. An affinity-optimized version of Synagis, motavizumab, has been subsequently developed. Since both Synagis and motavizumab bind the RSV fusion (F) protein, which plays a role in virus attachment and mediates the process of virus-cell fusion and cell-to-cell fusion, this study aimed to determine exactly how the drugs neutralize RSV. Four assays were used, which target four distinct steps during virus replication, to identify the mechanism.

• In Vitro and In Vivo Characterization of a Motavizumab-Resistant RSV A Mutant (#V-4148) F. J. Palmer-Hill, Tuesday, October 28, 2008, Hall C from 12:15 PM to 1:15 PM

BACKGROUND: This study investigated the growth characteristics – both in vitro and in vivo – of an RSV mutant that was created in the laboratory and is resistant to neutralization by motavizumab, an affinity-optimized MAb directed against the RSV fusion (F) protein. The F protein of the MAb differs from a wild type RSV F protein, so comparisons were made.

• Characterization of Respiratory Syncytial Virus (RSV)Mutants Resistant to Antibody Neutralization with Novel Amino Acid Changes in the RSV Fusion Protein (#V-4149) N. K. Patel, Tuesday, October 28, 2008, Hall C from 12:15 PM to 1:15 PM

BACKGROUND: Synagis is a MAb approved for the prevention of serious lower respiratory tract RSV infection in premature infants. Motavizumab was developed by affinity optimization of Synagis and is characterized by greater in vitro and in vivo neutralization activity against RSV. Previously, the selection of RSV mutants resistant to Synagis has been reported, characterized by amino acid changes in the RSV fusion (F) protein. This study sought to identify the selection and characterization of additional Synagis MAb-resistant mutants, as well as a novel motavizumab MAb-resistant mutant.

MedImmune abstracts to be presented at ICAAC/IDSA on influenza include:

• Influenza-like Illness and Employee Productivity – Results from the Child and Household Influenza-illness and Employee Function (CHIEF) (#K-4207) M. D. Rousculp, Tuesday, October 28, Room 150B from 2:450 PM to 3:00 PM

BACKGROUND: This prospective cohort study of nearly 2,293 U.S. households evaluated the effect of employee and household member influenza-like illness on worker productivity. The households studied were employees from three large Fortune 500 companies. All households included in the study had at least one child. Households were surveyed monthly throughout the 2007-2008 influenza season to determine the impact of influenza-like illness on employees’ work absenteeism and decreased productivity while on the job.

• Impact of Early and Late Influenza Vaccine Availability on In-Office Vaccination Opportunities (#G1-1208) R. Judelsohn, Sunday October 26, Hall C from 11:15 AM to 12:15 PM

BACKGROUND: The CDC now recommends all children from six months to 18 years of age receive an annual influenza vaccination; however, a key barrier to implementation is the inconvenience to parents and providers around scheduling additional office visits to administer the vaccination. This study examined how many more vaccination opportunities exist if influenza vaccination availability were expanded beyond the typical October-to-December timeframe.

• Benefits Versus Risks of Live Attenuated Influenza Vaccine (LAIV) in Young Children (#G1-1204) G. Oster, Sunday October 26, Hall C from 11:15 AM to 12:15 PM

BACKGROUND: In September 2007, approved use of LAIV in the U.S. was expanded to include children aged 24-59 months but with warning/precautions against use in younger children and children 24-59 months with a history of recurrent wheezing or asthma. Since some latter children may receive LAIV in clinical practice, its risks and benefits versus trivalent influenza vaccine (TIV) in this setting must be considered.

Additional information about the 2008 ICAAC/IDSA conference can be found at http://www.icaacidsa2008.org/.

About Synagis
Synagis(R) (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Synagis should not be used in patients with a history of severe prior reaction to Synagis or its components. Cases of severe allergic reactions such as anaphylaxis and other types of hypersensitivity reactions have been reported with Synagis. These reactions may occur when any dose of Synagis is given, not just the first one. Another serious side effect, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin, has been reported.

Most common side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) have also been reported.

Please see accompanying full prescribing information at http://www.synagis.com.

About FluMist
FluMist(R) (Influenza Virus Vaccine Live, Intranasal) is a live attenuated influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life- threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.flumist.com/prescribing-information.aspx for additional information.

About MedImmune
MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at http://www.medimmune.com.

Contacts:
Media: Tor Constantino, 301-398-5801
Investors: Peter Vozzo, 301-398-4358
http://www.medimmune.com

 All School-Age Children

GAITHERSBURG, Md., Aug. 4 /PRNewswire/ — MedImmune announced today that it began shipping FluMist(R) (Influenza Virus Vaccine Live, Intranasal) on July 31 for the 2008-2009 influenza season. Early and wide availability of FluMist is a key component in maximizing opportunities to vaccinate an additional 30 million children and teenagers through the age of 18 years who are now recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) to be vaccinated annually against influenza.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080804/NEM027 )

The CDC also advises that flu vaccine be administered every year as soon as it becomes available. Results of a recent analysis reported by MedImmune at the annual meeting of the Pediatric Academic Societies (PAS) revealed that starting vaccination against influenza in August may help reach an additional 10.7 million children while they are at healthcare provider offices for already-scheduled visits.

“To meet the goal of vaccinating every school-age child and teenager against the flu, vaccination practices must shift to include opportunities across a longer period of time,” said Norman “Chip” Harbaugh, M.D., F.A.A.P. of the Children’s Medical Group of Atlanta. “Early availability of FluMist gives providers the ability to reach more eligible children through back-to-school check-ups, sports physicals and annual well-child visits with a vaccine that has been shown to provide protection throughout the entire flu season.”

Record Number of FluMist Doses Available – and in More Locations

MedImmune will make FluMist more widely available than ever before, with plans to produce approximately 12 million doses for the 2008-2009 season. In addition to ongoing shipments to healthcare provider offices and clinics, FluMist will also be available this influenza season at select retail pharmacies and supermarkets. Please visit www.flumist.com for information about availability of FluMist in local areas.

FluMist will also be available in nearly 200 school-based vaccination programs and university health centers. Additionally, the U.S. Department of Defense (DoD) has awarded MedImmune a contract for FluMist for the fourth consecutive year to help vaccinate eligible active duty military personnel and their families.

FluMist is available in every state through the federally funded Vaccines for Children (VFC) program, which provides vaccines at no cost to eligible children. FluMist is also covered by approximately 94 percent of private health plans which offer immunization benefits.

About FluMist

FluMist is a live attenuated influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.medimmune.com/pdf/products/flumist_pi.pdf for additional information.

About MedImmune

MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune’s website at www.medimmune.com .

 SOURCE MedImmune -0- 08/04/2008 /NOTE TO EDITORS: In your coverage of influenza prevention, please recognize that the term "flu shot" is not an accurate way to report or describe influenza vaccinations. Please consider the more general term "flu vaccine" to cover both options available to people ages 2-49: the nasal spray influenza vaccine and the traditional flu shot. Please communicate this information to copy and headline editors. Images of FluMist are available upon request by contacting Karen Lancaster at 301-398-5864 or lancasterk@medimmune.com/ /CONTACT: Media, Karen Lancaster, +1-301-398-5864, or Investors, Peter Vozzo, +1-301-398-4358, both of MedImmune/ /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080804/NEM027 AP Archive: http://photoarchive.ap.org AP PhotoExpress Network: PRN10 PRN Photo Desk, photodesk@prnewswire.com/ /Web site: http://www.medimmune.com http://www.flumist.com http://www.flumist.com/prescribing-information.aspx / (AZN) CO: MedImmune; AstraZeneca plc; U.S. Centers for Disease Control and Prevention; CDC ST: Maryland IN: MTC HEA IDC SU: CHI LB-EE -- NEM027 -- 3728 08/04/2008 08:00 EDT http://www.prnewswire.com